MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
31.10
-0.38
-1.21%
After Hours: 31.55 +0.45 +1.45% 19:30 09/25 EDT
OPEN
31.48
PREV CLOSE
31.48
HIGH
31.71
LOW
30.65
VOLUME
2.02M
TURNOVER
--
52 WEEK HIGH
45.14
52 WEEK LOW
22.10
MARKET CAP
2.44B
P/E (TTM)
-7.1350
1D
5D
1M
3M
1Y
5Y
1D
Celldex price target raised to $88 from $70 at Leerink
TipRanks · 3d ago
Celldex Therapeutics Is Maintained at Outperform by Leerink Partners
Dow Jones · 3d ago
Celldex Therapeutics Price Target Raised to $88.00/Share From $70.00 by Leerink Partners
Dow Jones · 3d ago
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Benzinga · 3d ago
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
NASDAQ · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owlet (OWLT), Celldex (CLDX) and Edgewise Therapeutics (EWTX)
TipRanks · 3d ago
Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan Stanley
Dow Jones · 3d ago
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.